DE   EN   ES   FR   IT   PT


medicalmeds.eu Medicines Antioxidant means. Эмоксипин®

Эмоксипин®

Препарат Эмоксипин®. ФГУП "Московский эндокринный завод" Россия


Producer: Federal State Unitary Enterprise Moscow Endocrine Plant Russia

Code of automatic telephone exchange: C05CX

Release form: Liquid dosage forms. Solution for injections.

Indications to use: Hemorrhagic stroke. Ischemic stroke. Craniocereberal injury. Postoperative period. Acute myocardial infarction. Reperfusion syndrome. Unstable stenocardia.


General characteristics. Structure:

Active ingredient: 30 mg of a metiletilpiridinol of a hydrochloride (emoksipin) in 1 ml of solution.

Excipients: hydroxide sodium solution, water for injections.




Pharmacological properties:

Pharmacodynamics. The vasoprotective, reduces permeability of a vascular wall, is inhibitor of free radical processes, anti-hypoxanthomas and antioxidant. Reduces viscosity of blood and aggregation of thrombocytes, increases the maintenance of cyclic nucleotides (cyclic adenosinemonophosphate and cyclic guanozinmono-phosphate) in thrombocytes and tissue of a brain, has fibrinolitic activity, reduces a risk degree of development of hemorrhages, promotes their rassasyvaniye. Expands coronary vessels, in the acute period of a myocardial infarction limits necrosis center size, improves sokratitelny ability of heart and function of its carrying-out system.

With the increased arterial pressure renders hypotensive effect. At acute ischemic disorders of cerebral circulation reduces weight of neurologic symptomatology, increases resistance of fabric to a hypoxia and ischemia.

Pharmacokinetics. Distribution volume - 5,2 l. It is metabolized in a liver. An elimination half-life - 18 min. Clearance - 214,8 ml/min. It is removed by kidneys.


Indications to use:

In neurology and neurosurgery in complex therapy: a hemorrhagic stroke in the recovery period, an ischemic stroke, passing disturbances of cerebral circulation, chronic insufficiency of cerebral circulation, the craniocereberal injury (CI); the postoperative period at the patients with a craniocereberal injury operated concerning Epi - the subdural and intracerebral hematomas which are combined with a brain bruise.

In cardiology in complex therapy: acute myocardial infarction; prevention of a syndrome of reperfusion; unstable stenocardia.


Route of administration and doses:

In neurology and neurosurgery - drug Emoksipin is used intravenously kapelno with a speed of 20 - 30 thaws a minute in a daily dose by 10 mg/kg within 10-12 days. In the subsequent pass to intramuscular introduction 60-300 mg 2-3 times a day within 20 days. Before introduction the drug Emoksipin® is dissolved in 200 ml of solution of sodium of chloride isotonic.

In cardiology - intravenously kapelno with a speed of 20-40 thaws a minute in a dose of 600-900 mg of solution of drug Emoksipin in 200 ml of solution of sodium of chloride isotonic 1-3 once a day within 5-15 days depending on the course of a disease, with the subsequent transition to intramuscular introduction of 60-300 mg 2-3 times a day within 10-30 days.


Features of use:

Treatment should be carried out under control of arterial pressure and coagulability of blood.


Side effects:

Excitement, drowsiness, increase in arterial pressure, reaction in an injection site (pain, an itch, burning), a headache, pain in heart, allergic reactions, dyspepsia, blood coagulation disturbance.


Interaction with other medicines:

Pharmaceutical it is not compatible to other medicines.


Contraindications:

- the increased individual sensitivity to drug Emoksipin;
- pregnancy, lactation period;
- children up to 18 years.


Overdose:

Data on overdose are absent.


Storage conditions:

List B. In the place protected from light, at a temperature not above 25 °C. To store in the places unavailable to children. A period of validity - 2 years. Drug cannot be used after expiry date.


Issue conditions:

According to the recipe


Packaging:

Solution for intravenous and intramuscular administration of 30 mg/ml on 1 or on 5 ml in ampoules of neutral glass of the NS-1 or NS-3 brand or import. On 5 ampoules in a blister strip packaging from a film polyvinyl chloride and a foil of the aluminum printing varnished or flexible packaging on the basis of aluminum foil, or without foil. On 1 or 2 blister strip packagings (with a foil or without foil) together with the application instruction of drug, a knife or the scarificator ampoule place in a pack from a cardboard. On 20, 50 or 100 blister strip packagings with a foil (for a hospital) together with 10, 25 or 50 application instructions of drug respectively, knives or scarificators ampoule place in a box from a cardboard or in a box from corrugated fibreboard. When packaging ampoules with rings or points of a break knives or scarificators ampoule do not put.



Similar drugs

Препарат Лакэмокс. ФГУП "Московский эндокринный завод" Россия

Лакэмокс

Drugs for treatment of diseases of eyes. Other ophthalmologic means



Emoksipin

Antiagreganta. Antigipoksanta and antioxidants. Vasoprotectives, proofreaders of microcirculation.



Emoksipin

Antiagreganta. Antigipoksanta and antioxidants. Vasoprotectives, proofreaders of microcirculation.



Препарат Эмоксипин®. ФГУП "Московский эндокринный завод" Россия

Эмоксипин®

Drugs for treatment of diseases of eyes.





  • Сайт детского здоровья